BRPI0312649A2 - compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. - Google Patents

compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.

Info

Publication number
BRPI0312649A2
BRPI0312649A2 BRPI0312649A BR0312649A BRPI0312649A2 BR PI0312649 A2 BRPI0312649 A2 BR PI0312649A2 BR PI0312649 A BRPI0312649 A BR PI0312649A BR 0312649 A BR0312649 A BR 0312649A BR PI0312649 A2 BRPI0312649 A2 BR PI0312649A2
Authority
BR
Brazil
Prior art keywords
compounds
processes
pharmaceutical compositions
compositions containing
use therefor
Prior art date
Application number
BRPI0312649A
Other languages
English (en)
Portuguese (pt)
Inventor
A Townsend Craig
P Kuhadja Francis
Thupari Jagan
M Mcfadden Jill
M Medghalchi Susan
Original Assignee
Fasgen Llc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fasgen Llc, Univ Johns Hopkins filed Critical Fasgen Llc
Publication of BRPI0312649A2 publication Critical patent/BRPI0312649A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0312649A 2002-07-09 2003-07-09 compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. BRPI0312649A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
PCT/US2003/021700 WO2004005277A1 (en) 2002-07-09 2003-07-09 Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Publications (1)

Publication Number Publication Date
BRPI0312649A2 true BRPI0312649A2 (pt) 2017-05-16

Family

ID=30115739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312649A BRPI0312649A2 (pt) 2002-07-09 2003-07-09 compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.

Country Status (13)

Country Link
US (2) US7649012B2 (enExample)
EP (3) EP1539730A4 (enExample)
JP (3) JP2005533835A (enExample)
KR (1) KR101087559B1 (enExample)
CN (2) CN101602756B (enExample)
AU (1) AU2003265267B2 (enExample)
BR (1) BRPI0312649A2 (enExample)
CA (2) CA2491802C (enExample)
EA (1) EA013371B1 (enExample)
IL (2) IL166108A0 (enExample)
MX (1) MXPA05000365A (enExample)
SG (1) SG169236A1 (enExample)
WO (1) WO2004005277A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007556A (es) 2002-02-08 2005-12-05 Univ Johns Hopkins Med Estimulacion de cpt-1 como medio para reducir peso.
US20060135568A1 (en) * 2002-07-09 2006-06-22 Townsend Craig A Methods of treating microbial infections in humans and animals
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US20100168176A1 (en) * 2006-11-08 2010-07-01 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
EP2285215A4 (en) * 2008-06-02 2012-04-04 Fasgen Inc NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6228198B2 (ja) * 2012-06-25 2017-11-08 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 異常な脂質生合成シグナル伝達を有するがんを処置するための組成物および方法
WO2014039769A1 (en) * 2012-09-07 2014-03-13 Janssen Pharmaceutica Nv Imidazolin-5-one derivatives useful as fatty acid snthase (fasn) inhibitors for|the treatment of cancer
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
CA2968288A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
AU1044088A (en) * 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
MX9708597A (es) * 1995-05-09 1998-02-28 Bayer Ag Cetoenoles alquil-dihalogenofenil substituidos como pesticidas y herbicidas.
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−３−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
JP2004528341A (ja) 2001-05-02 2004-09-16 ニューヨーク・ユニバーシティ 脂肪酸合成酵素の阻害による色素形成の阻害
MXPA04007556A (es) * 2002-02-08 2005-12-05 Univ Johns Hopkins Med Estimulacion de cpt-1 como medio para reducir peso.
US20060135568A1 (en) 2002-07-09 2006-06-22 Townsend Craig A Methods of treating microbial infections in humans and animals
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Also Published As

Publication number Publication date
EP1539730A4 (en) 2007-03-28
CN101602756A (zh) 2009-12-16
IL166108A0 (en) 2006-01-15
CN101602756B (zh) 2014-11-12
KR20060002007A (ko) 2006-01-06
SG169236A1 (en) 2011-03-30
MXPA05000365A (es) 2005-09-20
IL190218A0 (en) 2008-11-03
EA013371B1 (ru) 2010-04-30
JP2011037881A (ja) 2011-02-24
AU2003265267A1 (en) 2004-01-23
US7649012B2 (en) 2010-01-19
EP2386551A1 (en) 2011-11-16
CN1675192A (zh) 2005-09-28
CA2491802A1 (en) 2004-01-15
JP2005533835A (ja) 2005-11-10
CA2767092C (en) 2013-10-15
WO2004005277A1 (en) 2004-01-15
KR101087559B1 (ko) 2011-11-29
CA2767092A1 (en) 2004-01-15
EP2386550A1 (en) 2011-11-16
US20060247302A1 (en) 2006-11-02
CA2491802C (en) 2012-04-10
US20100120901A1 (en) 2010-05-13
HK1083835A1 (zh) 2006-07-14
CN100513404C (zh) 2009-07-15
JP2013189464A (ja) 2013-09-26
EA200500178A1 (ru) 2006-02-24
EP1539730A1 (en) 2005-06-15
AU2003265267B2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
BR0300500B1 (pt) composiÇço poliolefÍnica, processo para estabilizaÇço de uma poliolefina e uso de uma mistura.
BRPI0407755B1 (pt) composiÇço catalÍtica, sua preparaÇço e uso
DK1399444T3 (da) Nye heterocycliske forbindelser, fremgangsmåde til fremstilling af samme samt anvendelse deraf som lægemidler, især som antibakterielle midler
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0009956B1 (pt) Composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
SE0301653D0 (sv) Novel compounds
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BR0214263B1 (pt) processos para a preparaÇço de uma composiÇço para o tratamento dos cabelos.
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
IS6986A (is) Lyfjasamsetning í vökvaformi
DK1500654T3 (da) Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
HUS1500006I1 (hu) Benzotiazol-származék vegyületek, kompozíciók és alkalmazások
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
BRPI0312413A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna

Legal Events

Date Code Title Description
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]